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Introduction {#sec1}
============

A major frontier in biomedicine and synthetic bioengineering is the development of computational and experimental tools for the rational design of interventions that drive desired changes in cell-, tissue-, and organ-level properties. Alongside well-known biochemical pathways, it is now known that bioelectric signaling driven by ion channel and pump proteins is a key determinant of growth, patterning, physiological maintenance, and repair ([@bib27], [@bib67]). The emerging field of molecular bioelectricity has revealed resting potential distributions across cell groups as a powerful instructive pathway for numerous events during embryogenesis, regenerative repair, and cancer suppression ([@bib48], [@bib49], [@bib65]). Cell differentiation, proliferation, migration, and tissue morphogenesis receive inputs from bioelectric circuits outside the nervous system, and it is now clear that the bioelectric state is a tractable and powerful master regulator that can be exploited for control of tissue and organ patterning in numerous contexts ([@bib47], [@bib80], [@bib67], [@bib6]). Recent work has revealed, for example, the control of human stem cell differentiation ([@bib87], [@bib88], [@bib89], [@bib90]), immune system function ([@bib51], [@bib75]), tumor normalization ([@bib21], [@bib20], [@bib19], [@bib22], [@bib23]), transplant innervation ([@bib8], [@bib9]), and conversion of gut tissue into a functional eye ([@bib71]) by specific modulation of bioelectric circuits that mediate signaling among cell networks ([@bib49], [@bib76]).

The possible modulation of these signals is increasingly becoming appreciated as a potential tool for regenerating tissue and curing disease including injury and cancer ([@bib68], [@bib45], [@bib82], [@bib25], [@bib11], [@bib94], [@bib84]). For example, Kirson et al. reported the discovery that low-intensity (1--3 V/cm), intermediate-frequency (100--300 kHz) electric fields have a profoundly inhibitory effect on the growth rate of various mammalian tumor cell lines. This discovery has been translated into a clinical application termed "tumor-treating fields" for the treatment of glioblastoma multiforme ([@bib40], [@bib38], [@bib39]). Several ion channel drugs are also now being used to combat cancer ([@bib26], [@bib44], [@bib18], [@bib36]). Numerous beneficial medical applications of electrical signals can be envisioned in the context of therapeutic use. However, a major challenge is to understand and guide the complexity of biophysical interactions induced by external field stimulation. Thus recent applications of bioelectricity to therapeutic contexts have focused on control of endogenous cellular ionic and voltage gradients by modulating ion channel function.

Work in amphibian model systems (e.g., *Xenopus laevis*) has revealed that misexpression of carefully selected ion channels can repair brain defects due to teratogenic insult ([@bib74]) or even mutation ([@bib72], [@bib73]), reprogram and suppress oncogene-mediated tumorigenesis ([@bib21], [@bib20], [@bib22], [@bib23]), augment innate immune system function ([@bib75]), expand neural connectivity and function of implanted tissues ([@bib8], [@bib9]), and induce regeneration of whole appendages, including the spinal cord and muscles ([@bib1]). Moreover, the existence of a plethora of pharmacological agents targeting ion channels allows small molecule approaches that achieve the desired bioelectric state change without the need for gene therapy using exogenous channel proteins. Successful examples include the induction of whole leg regeneration in *Xenopus* by an ionophore cocktail ([@bib92]), the use of ion channels in human tissues *in vitro* ([@bib51], [@bib70], [@bib87], [@bib89], [@bib91]), and the increasing use of ion channel drugs as anti-cancer agents in mammals ([@bib31], [@bib32], [@bib33], [@bib42], [@bib41], [@bib10], [@bib3], [@bib85], [@bib2]).

The most attractive feature of bioelectric signaling is that it frequently serves as a master regulator that rapidly triggers very complex, highly coordinated downstream programs that do not have to be micromanaged ([@bib76], [@bib77], [@bib48], [@bib30]). In addition to such applications in regulating growth and patterning, a plethora of applications in neurology, cardiology, and other aspects of pathophysiology await tools that enable efficient control of ionic signaling and bioelectric state within and across tissues.

Thus, we and others have proposed a roadmap ([Figure 1](#fig1){ref-type="fig"}) of using predictive modeling platforms ([@bib12], [@bib13], [@bib15], [@bib16], [@bib14], [@bib17], [@bib28], [@bib78], [@bib79], [@bib80], [@bib74], [@bib50]) for the development of rational control of patterning in biomedical contexts by ion channel modulators or "electroceuticals." Specifically, given the knowledge of the bioelectric state corresponding to the desired (healthy) form and function of a given tissue, one can use predictive physiological simulators ([@bib17], [@bib78]) to determine which ion channels should be opened or closed to reprogram the bioelectric circuit from its current (diseased or immature) state into a desired state, with the concomitant downstream changes in transcriptional and epigenetic profile. One benefit is that many ion-channel-modulating pharmacological agents are already approved by the United States Food and Drug Administration (FDA) for human use in arrhythmias, epilepsy, and other conditions ([@bib5], [@bib35], [@bib66], [@bib93]) and thus can be repurposed for bioelectrical control in regenerative medicine and other applications. In addition to developing technology for localized delivery ([@bib83], [@bib64], [@bib24]), the needed effects can also be achieved with systemic delivery: effects can be largely focused on one tissue by taking advantage of unique channels or pumps that are only expressed in that cell type(s) ([@bib92], [@bib7], [@bib54]).Figure 1Schematic of Approach for Design of Electroceuticals in Regenerative Medicine(A) First, the current bioelectric state of the tissue is ascertained using techniques like voltage reporter fluorescent dyes (A′) or traditional electrophysiology. This is compared with the correct (healthy) state of the same tissue (B, B′); to determine what ion flows would convert the current (disease) state to the healthy bioelectric state (C), computational models (physiological simulators, C′) are used. The EDEn system facilitates the subsequent steps: identify specific ion channels and pumps that, if modulated, would implement the needed change in ion currents (D), and determine drugs that target those electrogenic proteins in the desired way (E). The predicted small molecule blends are then tested (F) to validate the strategy before biomedical deployment.

Equally important is the identification of channels that could protect other tissues in a proposed electroceutical strategy (e.g., what combination of drugs will hyperpolarize nascent metastatic cells without affecting heartbeat in cardiac tissue). However, a major barrier to the broad use of these strategies is the lack of computational tools for rapidly ascertaining relevant targets in a tissue of interest and identifying existing small molecule compounds that could modulate the electrogenic proteins in those cells in the ways needed to achieve a desired bioelectric state. To design an electroceutical strategy, one first needs to know which channels and pumps are present in which tissue and what reagents exist to modulate them specifically. This is an essential first-step information that needs to be fed into a predictive computational model ([@bib17], [@bib78], [@bib79], [@bib80], [@bib74], [@bib50]). The proliferation of computational tools and databases designed to assist with genomic and biochemical approaches has not yet been extended to assist scientists with designing bioelectrical and physiological interventions.

Here we report the first platform front-end designed to accelerate the design of electroceuticals and their blends. The electroceutical design environment (EDEn) ion channel database and web server is a tool that researchers can use to obtain information about ion channels expressed in a specific tissue or cell type (both healthy and in a range of disease states). Having thus obtained a list of potential ion channel and pump targets, the user can then rapidly identify a list of available pharmacological agents (ideally FDA-approved drugs) for their modulation. This method enables selection of channels with desired tissue specificity and availability of blockers/activators with desired properties. This information can then be fed into existing simulators ([@bib78], [@bib79]); currently, such iterative search must be performed manually, which greatly delays the process and is prone to human error. The EDEn database works together with the web server providing a graphical front end that can be used to access information contained in the database. The database integrates data from multiple public data sources, and updated data can be added to the database in an automated fashion as new profiling, genomic, and drug data are reported. This platform can be used for biomedical purposes, as well as to identify reagents for control of cell behavior in bioengineering, synthetic biology, and numerous other contexts *in vitro* and *in vivo*. Thus this versatile tool significantly lowers the entry barrier for workers in basic and applied physiology, seeking to identify targets and reagents for pilot experiments or large focused studies.

Results {#sec2}
=======

Database Schema {#sec2.1}
---------------

The database is a relational database. The database schema is illustrated in [Figure 2](#fig2){ref-type="fig"}. The core of the database is data centered on human tissue types and human ion channels. This data are stored in two tables, the Tissue table and the Protein table.Figure 2Schema of the EDEn DatabaseTables are shown as rectangular boxes. Relations between tables are shown as lines. Multiplicity of table relationships is shown using Crow\'s Foot notation.

The Tissue table ([Figure 3](#fig3){ref-type="fig"}) contains data about a variety of human tissue and cell types, both referred to as tissues in the platform. The tissues that were selected for inclusion in the platform were those for which expression data were available. The names of the tissues are based on the Brenda Tissue Ontology ([www.brenda-enzymes.org/ontology.php?ontology_id=3](http://www.brenda-enzymes.org/ontology.php?ontology_id=3){#intref0010}) ([@bib29]). The Tissue table includes both healthy tissue types and cancer tissue types. The database supports hierarchical relationships between tissues (for example, the brain is a part of the central nervous system); however, this information is currently not used by the web front end. A supporting table, DBTissue, is used to associate the tissue names used by the platform with the names or IDs used by the data sources.Figure 3Tissue TableA schematic representation of the tissue table in the EDEn database. Tables are shown as rectangular boxes. Fields are shown as ovals. Primary keys are underlined and marked with (PK). Multiplicity of table relationships is shown using Crow\'s Foot notation.

The Protein table ([Figure 4](#fig4){ref-type="fig"}) contains data about human ion channel proteins and the corresponding genes. The ion channel data is protein centric, with the UniProt accession number used as the primary key for Protein table. The table includes information important for the platform, including a Boolean field that records if the ion channel has parameters for simulation in BETSE (BioElectric Tissue Simulation Engine; [@bib78]). One limitation of the current data model is that information about ion channels that consist of a complex of proteins is not handled. Two supporting tables, ChannelSubClass (see below) and GoTerm, are used to store classification information about the ion channels. The GoTerm table has relevant terms from the Gene Ontology database ([@bib4]).Figure 4Protein TableA schematic representation of the protein table in the EDEn database. Tables are shown as rectangular boxes. Fields are shown as ovals. Primary keys are underlined and marked with (PK). Foreign keys are marked with (FK). Multiplicity of table relationships is shown using Crow\'s Foot notation.

The Expression table ([Figure 5](#fig5){ref-type="fig"}) associates a record in the Tissue table with a record in the Protein table. The table contains information about the abundance of each ion channel in each tissue. The intent of this information is that it can be used to identify ion channel targets for a particular tissue known to the user. The table supports both quantitative expression information and categorical expression information. The categorical expression data have four expression levels: high, medium, low, and not detected. The database design supports multiple expression records for each Tissue-Protein pair. If multiple records exist, then the web interface prefers to use quantitative data when available. One limitation of the current approach is that combining expression data from multiple sources is not currently possible. The supporting table ExternalDB is used to store information about the data source for the expression data.Figure 5Expression tableA schematic representation of the expression table in the EDEn database. Tables are shown as rectangular boxes. Fields are shown as ovals. Primary keys are underlined and marked with (PK). Foreign keys are marked with (FK). Possible values for some fields are also shown. Multiplicity of table relationships is shown using Crow\'s Foot notation.

The Specificity table ([Figure 6](#fig6){ref-type="fig"}) is based on the expression data. This table contains a specificity score for each Tissue-Protein pair in the database that has quantitative expression data. The score is a calculated value wherein higher numbers correspond to ion channels that tend to be highly expressed only in the associated tissue and not in many other tissues and lower numbers correspond to ion channels that have high expression in many tissues, that is, those that are ubiquitously expressed.Figure 6Specificity TableA schematic representation of the specificity table in the EDEn database. Tables are shown as rectangular boxes. Fields are shown as ovals. Primary keys are underlined and marked with (PK). Foreign keys are marked with (FK). Multiplicity of table relationships is shown using Crow\'s Foot notation.

The Compound table ([Figure 7](#fig7){ref-type="fig"}) contains data about each compound (including approved or investigational drugs). Each compound is classified as either a "compound" or a "drug" based on its categorization in the ChEMBL database. The Name field of the table is the primary name of the compound; in the case of the drug, this is the drug common name, and in the case of other compounds, this is generally an International Union of Pure and Applied Chemistry (IUPAC) name. The Synonym field of the table is a list of zero or more alternate names for the compound, for example, a trade name of a drug or an IUPAC name. A future version of the database is planned to include additional information about each compound, including a chemical structure in SMILES or InChI format, and allow the user to view the chemical structure in the web interface. The ExternalDB table is used to link the Compound table with the data source for the compound; in the current version of the database this is always ChEMBL. It should be mentioned that for practical applications such as *in vitro* assays involving some of the compounds found in this database, additional information about their properties needs to be acquired from additional resources available both publicly (e.g., <https://www.drugbank.ca>) or commercially (e.g., ADMET Predictor from <https://www.simulations-plus.com/software/admetpredictor/>). These resources can inform the interested user regarding both the pharmacokinetic and pharmacodynamic properties of the compounds in question, some of which may be FDA-approved drugs. For example, the log p values, the solubility value, the blood-brain barrier permeability coefficient, or the diffusion coefficient can all be estimated using *in silico* prediction, or in some cases found from experimental data sources.Figure 7Compound TableA schematic representation of the chemical compound table in the EDEn database. Tables are shown as rectangular boxes. Fields are shown as ovals. Primary keys are underlined and marked with (PK). Foreign keys are marked with (FK). Possible values for some fields are also shown. Multiplicity of table relationships is shown using Crow\'s Foot notation.

The Interaction table ([Figure 8](#fig8){ref-type="fig"}) contains data about the interaction of a Protein-Compound pair. The ActionType field includes information about the type of interaction (e.g., blocker, activator, modulator). The intent of this table is that once the user has identified an ion channel target (or targets), he or she will then use the platform to search for compounds that have an effect on the target. The strength of the interaction is stored in the AssayValue field, which is a parameter calculated from an appropriate assay of the compound with the protein. The assay values are generally IC~50~ values, but they may also include EC~50~, *K*~*i*~, or *K*~*d*~ values. A limitation of the current approach is that specificity information about compounds for ion channel targets is not used by the platform, that is, the platform can be used to identify compounds that are potent against a given target, but the identified compound may also be potent against other ion channels that the user does not intend to target. The information in this table is based on assay data from the ChEMBL database.Figure 8Interaction TableA schematic representation of the protein-drug interaction table in the EDEn database. Tables are shown as rectangular boxes. Fields are shown as ovals. Primary keys are underlined and marked with (PK). Foreign keys are marked with (FK). Multiplicity of table relationships is shown using Crow\'s Foot notation.

Last, the ChannelSuperClass, ChannelClass, and ChannelSubClass tables (see [Figure 9](#fig9){ref-type="fig"}) are used to store hierarchical information about a hierarchical classification of ion channels. For example, SuperClass = K (potassium), Class = Kv1, and SubClass = Kv1.1. The six superclasses are chloride, potassium, sodium, calcium, proton channels, and non-selective cation channels. The 27 classes and 169 subclasses can be found in [channelpedia.epfl.ch](http://channelpedia.epfl.ch){#intref0020}.Figure 9Channel Class TablesA schematic representation of the channel class tables in the EDEn database. Tables are shown as rectangular boxes. Fields are shown as ovals. Primary keys are underlined and marked with (PK). Foreign keys are marked with (FK). Multiplicity of table relationships is shown using Crow\'s Foot notation.

The number of records in each table is given in [Table 1](#tbl1){ref-type="table"}.Table 1Total Number of Records in the Main Database TablesTableNo. of RecordsTissue120Protein747Compound33,483Expression79,830Specificity35,475Interaction103,048GoTerm2,177ChannelSuperClass6ChannelClass27ChannelSubClass169[^2]

Web Server {#sec2.2}
----------

The web server provides a graphical user interface to the ion channel database. [Figure 10](#fig10){ref-type="fig"} is a screenshot of the web interface. [Figure 11](#fig11){ref-type="fig"} shows a typical screenshot of the results. The main use case supported by the web interface is described in the text that follows:1.The user selects one or more tissues.2.The user selects an expression threshold. Only ion channels with expression greater than or equal to the threshold will be shown. This option only works when quantitative expression data are available. In addition, the user may select the option "Include BETSE ion channels?". If this option is selected, all ion channels that are supported in BETSE will be shown, ignoring the expression threshold for those ion channels. This feature is included as part of integration with the most comprehensive modeling package (BETSE).3.Select Comprehensive to show all channels expressed in the selected tissues (ordered by the most specific first). Select Unique to show only channels that are specific to the selected tissues. (This feature will be implemented in the future.)4.Select one or more ion channels. Info about the selected ion channel from Channelpedia will be shown in the panel on the right, if available.5.Click Lookup. The requested data will be retrieved from the database and displayed in a table to the user.Figure 10A Representative Screenshot of the Web InterfaceFigure 11A Typical Screenshot of the Results Generated by EDEn

The web server and database are running on an Amazon Web Services instance. The operating system is Ubuntu 16.04 LTS Linux. The web server was built using the Django web framework. Django is a Python-based web framework. The Apache HTTP server is also used as part of the web stack. The Django web code interfaces with the Python database access routines. The web server also uses JavaScript, jQuery, and Ajax to update the page without reloading. The source code is maintained in a public GitHub repository. The web server is free to access.

Discussion {#sec3}
==========

Design of next-generation biomedical interventions, especially those with the advantage of not involving gene therapy, will require a tight integration of genetic, biochemical, and physiological data. We present a contribution to the developing fields of bioelectricity and functional bioinformatics, which facilitate the discovery of strategies to manage system-wide physiological signaling. Existing examples of this approach are the repolarization of KRAS mutation-induced tumors (normally depolarized), which results in the prevention or normalization of tumorigenesis ([@bib21], [@bib20], [@bib19], [@bib22], [@bib23], [@bib52]), and the forced bioelectric prepattern (induced by activating HCN2 channel function), which results in normal embryonic brain development despite the presence of mutations and chemical teratogens, which reduce the resting potential difference between nascent brain cells and nearby tissues ([@bib72], [@bib73], [@bib74]).

Understanding the real-time dynamics of bioelectric signals in a tissue is extraordinarily complex given the voltage sensitivity of ion channels and gap junctions and the intricacy of the resulting feedback loops. To address the need for a biorealistic model, members of our team have previously developed the BETSE ([@bib78]), which has already led to the successful discovery of agents that repair brain morphology and function despite a range of diverse teratogenic insults ([@bib74]). Such tools model ion channel and gap junction activity to predict bioelectric patterns across tissues, and the resulting changes to membrane potential upon modulation of channels. As inputs to the strategy of using these models to design interventions targeting specific body tissues and organs, knowledge of tissue-specific channel expression and availability of relevant functional small molecules is required. The EDEn database is an essential input to pipelines that use simulators and other strategies to design pharmacological interventions, to enable the modeling components to know which native electrogenic components to model and which can be targeted. Our database allows users to rapidly (1) determine the expression of ion channels in target tissues, thus acquiring a (ranked) list of potential targets for manipulation *in vivo* and (2) identify existing compounds known to modulate a given channel, and their specific effect on that channel (a required step for implementing the designed strategies).

In its current stage (v1.0), it is an essential tool for human users creating physiological models of specific organs/tissues in health and disease, and designing interventions based on those models. However, another use case for this system is as part of an artificial intelligence tool, in which automated approaches ([@bib86], [@bib81], [@bib37]) use this information to help design interventions. Subsequent development will automate the integration of the EDEn system with machine-learning-based model discovery platforms ([@bib60], [@bib61], [@bib55], [@bib56], [@bib57], [@bib62], [@bib59], [@bib58], [@bib53]), to enable high-efficiency automated discovery of candidate drug blends in a broad range of biomedical scenarios.

Future versions of EDEn will also add significant new functionality, besides being continuously updated with the latest information in the growing channel expression and drug databases. First, the growing number of cell resolution profiling efforts will enable distinct information on single-cell profiles versus complex tissue and organ contexts (for example, the expression database contains mRNA data from single cell types as well as from heterogeneous tumors). Second, increasing data on structure-function relationships in ion channels and pumps will allow inclusion of data on drug effects on mutated channels, and on non-ion-passing functions of channel proteins (which can easily be accommodated by including such signaling in the simulation steps). Third, the database will be extended to powerful model species such as mouse, *Xenopus*, zebrafish, etc. Finally, we will be including forthcoming proteomic and physiomic datasets, to improve accuracy given the fact that mRNA expression data are only an estimate of the eventual bioelectric state of the cell (given the many steps involved, such as differential splicing, translation, membrane targeting, and gating).

One of the major questions for applications of bioelectrics to medicine is "how can we apply bioelectric manipulations in the patient, without using transgenics to introduce new ion channels as gene therapy, in patients"? A powerful set of strategies is to use rationally designed combinations of ion channel drugs to open and close specific endogenous ion channels to produce bioelectrical distributions that drive desirable downstream cell behaviors. Remarkably, such approaches have already been used to repair even genetic defects such as mutant NOTCH and KRAS proteins ([@bib21], [@bib20], [@bib22], [@bib23], [@bib73]). How can we determine which drugs to use? The answer requires at least two components: (1) knowing which channels are present in the target tissue (and how to use that information to avoid untoward side effects in other organs) and (2) inferring what pattern of channel opening and closing must be achieved to make the necessary bioelectric state happen. The goal of this research was to create a software system to assist with the development of such strategies. This platform will suggest (a combination of) channel drugs that preferentially targets the tissue in question and sets up the desired bioelectric state, capitalizing on differences in channel expression and availability of lots of drugs with overlapping specificities. The EDEn database enables the execution of such a program. This will require an integration of EDEn with the physiological simulator BETSE. The ultimate goal is to turn the combination of products into a turnkey system for predicting drug cocktails, exploiting known drugs (many of which are already human approved) and the battery of compounds sitting unused in drug companies, which "failed" unsophisticated tests ([@bib63], [@bib34], [@bib69], [@bib43], [@bib36]). This database makes such an approach possible ([@bib46]).

Limitations of the Study {#sec3.1}
------------------------

In this article, we report the first platform front-end designed to accelerate the design of electroceuticals. The EDEn ion channel database and web server is a tool that researchers can use to obtain information about ion channels expressed in a specific tissue or cell type (both healthy and in a range of disease states). This is a versatile tool that significantly lowers the entry barrier for workers in basic and applied physiology seeking to identify targets and reagents for pilot experiments or large focused studies. However, there are several limitations, which will be addressed by updating EDEn in the future. First, the current data model does not handle information about ion channels that consist of a complex of different proteins. Second, the ability to combine expression data from multiple sources is not currently implemented. Furthermore, specificity information about compounds for ion channel targets is not used by the platform; that is, the platform can be used to identify compounds that are potent against a given target, but the identified compound may also be potent against other ion channels that the user does not intend to target.

Data and Software Availability {#sec3.2}
------------------------------

The web server may be accessed at <http://eden.pharmamatrix.ca>. The source code for the database and web server are available at <https://github.com/pwinter3/IonChannel.git> and <https://github.com/pwinter3/IonChannelWeb.git>, respectively.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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